Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUAN C GARZA

Allopathic & Osteopathic Physicians Family Medicine

NPI
1669449971
CMS profile
165973
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$697.42

45 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $690.30 44
Education $7.12 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUAN C GARZA

NPI 1669449971 · CMS profile ID 165973

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669449971?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669449971?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669449971?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1669449971?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

45 matching records · $697.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 45 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–45 of 45.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $13.7212/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699275849 CMS
AstraZeneca Pharmaceuticals LP $11.0812/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685512623 CMS
Novo Nordisk Inc $16.3612/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674690469 CMS
Novo Nordisk Inc $18.4712/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674690465 CMS
PFIZER INC. $7.3711/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673776597 CMS
Novartis Pharmaceuticals Corporation $12.4611/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659633689 CMS
PFIZER INC. $1.1211/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673681801 CMS
PFIZER INC. $3.1910/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672908141 CMS
Teva Pharmaceuticals USA, Inc. $5.7110/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697741481 CMS
Novo Nordisk Inc $13.3809/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674555303 CMS
AstraZeneca Pharmaceuticals LP $10.8109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685963659 CMS
AstraZeneca Pharmaceuticals LP $13.1508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685383907 CMS
PFIZER INC. $2.2608/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672572687 CMS
Novo Nordisk Inc $16.1008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674594565 CMS
PFIZER INC. $3.7108/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672476927 CMS
Amarin Pharma Inc. $18.5707/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699190045 CMS
Janssen Pharmaceuticals, Inc $16.9907/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658617225 CMS
PFIZER INC. $0.6007/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672480097 CMS
Amarin Pharma Inc. $15.9507/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699167351 CMS
Janssen Pharmaceuticals, Inc $12.5506/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658617213 CMS
Avanir Pharmaceuticals, Inc. $19.0006/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653600471 CMS
PFIZER INC. $1.2206/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672471977 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.5106/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681812091 CMS
Astellas Pharma US Inc $19.5805/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655570102 CMS
Lilly USA, LLC $12.3005/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657939077 CMS
Novo Nordisk Inc $12.9004/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669541815 CMS
PFIZER INC. $3.1404/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672473949 CMS
Avanir Pharmaceuticals, Inc. $21.9504/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653600089 CMS
SANOFI-AVENTIS U.S. LLC $19.9104/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694006607 CMS
ARBOR PHARMACEUTICALS, INC. $15.8003/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697404965 CMS
Merck Sharp & Dohme Corporation $16.9703/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695324283 CMS
Teva Pharmaceuticals USA, Inc. $2.1403/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697690293 CMS
Amarin Pharma Inc. $22.0703/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699093097 CMS
PFIZER INC. $1.0802/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672481641 CMS
Allergan Inc. $11.2802/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670393841 CMS
SANOFI-AVENTIS U.S. LLC $13.5102/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693931753 CMS
Allergan Inc. $18.7402/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670393839 CMS
Teva Pharmaceuticals USA, Inc. $116.5702/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697870359 CMS
Lilly USA, LLC $13.8401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942445 CMS
AstraZeneca Pharmaceuticals LP $69.4801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685138373 CMS
AstraZeneca Pharmaceuticals LP $11.9601/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685901687 CMS
Novartis Pharmaceuticals Corporation $13.1501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659633687 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.1201/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681684907 CMS
PFIZER INC. $0.8001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672481131 CMS
Novo Nordisk Inc $22.8501/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668749869 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $697.42 45
PY2020 $462.87 34
PY2021 $606.41 45
PY2022 $1,514.63 68
PY2023 $1,566.78 94
PY2024 $1,681.91 93
PY2025 $1,387.30 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $43,373.43 14
PY2024 Principal investigator $171,802.76 70
PY2023 Recipient $23,812.92 7
PY2023 Principal investigator $383,116.06 124
PY2022 Principal investigator $624,521.08 179
PY2021 Principal investigator $663,885.83 360
PY2020 Principal investigator $248,213.43 166
PY2019 Principal investigator $403,386.63 210

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

179 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $101,227.31 12/31/2022 Non-covered Recipient Entity
VIP TRIALS
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 940398717
Principal investigator 1 Merck Sharp & Dohme LLC $5,954.64 12/31/2022 Non-covered Recipient Entity
VIP TRIALS
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 940398719
Principal investigator 1 Merck Sharp & Dohme LLC $310.34 12/31/2022 Non-covered Recipient Entity
VIP Trials
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 964706011
Principal investigator 1 Eli Lilly and Company $163.00 12/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 917849257
Principal investigator 1 Novo Nordisk AS $853.20 12/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897119781
Principal investigator 1 Novo Nordisk AS $373.50 12/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897232611
Principal investigator 1 Novo Nordisk AS $3,078.61 12/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897252663
Principal investigator 1 ABBVIE INC. $1,138.05 12/15/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889825905
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896856775
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896856777
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896894771
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896895465
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896895469
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896930125
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896930255
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896930260
Principal investigator 1 Novo Nordisk AS $15.98 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896951577
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896952947
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896952951
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896952955
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896952959
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896952963
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896953524
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896953529
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896953533
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961349
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961353
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961357
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961365
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897094779
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897135099
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897159191
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897159195
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897201333
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897203369
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897203373
Principal investigator 1 Novo Nordisk AS $15.98 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897248707
Principal investigator 1 Novo Nordisk AS $10.82 12/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897248711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,750.00 12/09/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086707
Principal investigator 1 ABBVIE INC. $2,948.40 12/06/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889823137
Principal investigator 1 Merck Sharp & Dohme LLC $145,467.03 12/05/2022 Non-covered Recipient Entity
VIP TRIALS LLC VIP TRIALS
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 940398681
Principal investigator 1 Novo Nordisk AS $1,582.94 12/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897207177
Principal investigator 1 ABBVIE INC. $1,250.00 12/01/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889822899
Principal investigator 1 Novo Nordisk AS $3,682.54 11/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896857623
Principal investigator 1 Novo Nordisk AS $826.87 11/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897094775
Principal investigator 1 Novo Nordisk AS $3,628.80 11/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897119777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $800.00 11/23/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,379.60 11/23/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086699
Principal investigator 1 ABBVIE INC. $1,309.55 11/09/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889820443
Principal investigator 1 Novo Nordisk AS $4,120.51 10/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896959469
Principal investigator 1 Novo Nordisk AS $2,767.50 10/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897135095
Principal investigator 1 Novo Nordisk AS $285.00 10/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897139409
Principal investigator 1 ABBVIE INC. $4,838.05 10/12/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889815333
Principal investigator 1 PFIZER INC. $2,080.35 10/12/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949795149
Principal investigator 1 Novo Nordisk AS $3,934.78 09/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897252435
Principal investigator 1 Novo Nordisk AS $9,782.33 09/28/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897114969
Principal investigator 1 Novo Nordisk AS $2,854.10 09/28/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897201389
Principal investigator 1 PFIZER INC. $1,602.45 09/23/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949795151
Principal investigator 1 Novo Nordisk AS $23.06 09/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900723
Principal investigator 1 Novo Nordisk AS $2.97 09/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896959465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,704.20 09/19/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086673
Principal investigator 1 ABBVIE INC. $6,681.95 09/08/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889810635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,737.20 08/24/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086681
Principal investigator 1 PFIZER INC. $5,011.08 08/23/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949801583
Principal investigator 1 Novo Nordisk AS $23.06 08/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896956777
Principal investigator 1 Novo Nordisk AS $2.75 08/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896973943
Principal investigator 1 PFIZER INC. $2,350.35 08/11/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949804595
Principal investigator 1 ABBVIE INC. $6,009.05 08/10/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889804913
Principal investigator 1 Novo Nordisk AS $23.06 08/10/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961361
Principal investigator 1 Novo Nordisk AS $2.97 08/05/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896857619
Principal investigator 1 Novo Nordisk AS $23.06 08/05/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902225
Principal investigator 1 Novo Nordisk AS $23.06 08/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900407
Principal investigator 1 Novo Nordisk AS $2.97 08/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896969353
Principal investigator 1 Novo Nordisk AS $383.94 07/27/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896959461
Principal investigator 1 Novo Nordisk AS $450.00 07/27/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897135091
Principal investigator 1 Novo Nordisk AS $891.22 07/27/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897207173
Principal investigator 1 Novo Nordisk AS $5.20 07/26/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900063
Principal investigator 1 Novo Nordisk AS $23.06 07/26/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902233
Principal investigator 1 Novo Nordisk AS $2.75 07/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896857621
Principal investigator 1 Novo Nordisk AS $23.06 07/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902229
Principal investigator 1 Novo Nordisk AS $23.06 07/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 897203365
Principal investigator 1 ABBVIE INC. $2,275.05 07/07/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889798793
Principal investigator 1 Novo Nordisk AS $767.88 06/29/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896972048
Principal investigator 1 Novo Nordisk AS $3,603.49 06/29/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897233893
Principal investigator 1 PFIZER INC. $1,872.45 06/25/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949810437
Principal investigator 1 Novo Nordisk AS $14.98 06/17/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896962079
Principal investigator 1 ABBVIE INC. $4,878.65 06/08/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889794461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $200.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $459.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $360.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $208.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,699.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $325.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $456.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $42.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 06/08/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $300.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $969.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $312.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,398.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $684.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $42.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,125.00 06/03/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,049.40 06/01/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086567
Principal investigator 1 PFIZER INC. $1,872.45 05/27/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949755179
Principal investigator 1 Novo Nordisk AS $7,334.64 05/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897119449
Principal investigator 1 Novo Nordisk AS $4,615.83 05/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897233889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $357.00 05/11/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $280.00 05/11/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086483
Principal investigator 1 PFIZER INC. $1,987.20 05/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949755183
Principal investigator 1 ABBVIE INC. $24.30 05/05/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889790401
Principal investigator 1 Novo Nordisk AS $4,560.85 04/29/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896997883
Principal investigator 1 PFIZER INC. $4,077.00 04/27/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949819525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,969.50 04/22/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086559
Principal investigator 1 ABBVIE INC. $10,841.55 04/07/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889784641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,071.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $840.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $416.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,398.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $650.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $912.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $84.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 04/06/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086551
Principal investigator 1 Novo Nordisk AS $6,543.61 03/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902333
Principal investigator 1 Novo Nordisk AS $823.50 03/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896930248
Principal investigator 1 Novo Nordisk AS $285.00 03/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897206559
Principal investigator 1 Novo Nordisk AS $2.75 03/24/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902237
Principal investigator 1 Novo Nordisk AS $23.06 03/24/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896938539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,093.40 03/23/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086067
Principal investigator 1 ABBVIE INC. $65,698.60 03/17/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889782009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26,113.50 03/11/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,212.40 03/11/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 03/11/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086047
Principal investigator 1 ABBVIE INC. $18,309.45 03/08/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $975.00 03/02/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $160.00 03/02/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 03/02/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085929
Principal investigator 1 Novo Nordisk AS $19.99 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900075
Principal investigator 1 Novo Nordisk AS $2.55 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896938525
Principal investigator 1 Novo Nordisk AS $4.50 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896938534
Principal investigator 1 Novo Nordisk AS $4.50 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896959471
Principal investigator 1 Novo Nordisk AS $18.00 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896959475
Principal investigator 1 Novo Nordisk AS $3.25 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896969357
Principal investigator 1 Novo Nordisk AS $30.00 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896973947
Principal investigator 1 Novo Nordisk AS $2.75 02/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902221
Principal investigator 1 Novo Nordisk AS $25.06 02/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896937910
Principal investigator 1 Novo Nordisk AS $1,125.75 02/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896958181
Principal investigator 1 Novo Nordisk AS $4,163.39 02/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897166499
Principal investigator 1 Novo Nordisk AS $500.00 02/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897233885
Principal investigator 1 Novo Nordisk AS $2.97 02/17/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902217
Principal investigator 1 Novo Nordisk AS $25.06 02/17/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896956773
Principal investigator 1 Novo Nordisk AS $25.06 02/14/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900059
Principal investigator 1 Novo Nordisk AS $5.20 02/14/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896959457
Principal investigator 1 PFIZER INC. $3,859.65 02/12/2022 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949830401
Principal investigator 1 Novo Nordisk AS $25.06 02/09/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961345
Principal investigator 1 Novo Nordisk AS $522.50 02/09/2022 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 897252659
Principal investigator 1 Novo Nordisk AS $1,000.00 02/07/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896856747
Principal investigator 1 Novo Nordisk AS $130.00 02/07/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896856771
Principal investigator 1 Novo Nordisk AS $1,000.00 02/07/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902201
Principal investigator 1 Novo Nordisk AS $2.75 02/04/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900055
Principal investigator 1 Novo Nordisk AS $25.06 02/04/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896901319
Principal investigator 1 Novo Nordisk AS $2.75 02/04/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896956971
Principal investigator 1 Novo Nordisk AS $25.06 02/04/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896973939
Principal investigator 1 ABBVIE INC. $614.25 02/03/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889775949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,900.00 02/02/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085853
Principal investigator 1 Novo Nordisk AS $25.06 02/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896900051
Principal investigator 1 Novo Nordisk AS $2.75 02/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896902209
Principal investigator 1 Novo Nordisk AS $25.06 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 896997889
Principal investigator 1 Novo Nordisk AS $25.06 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897071117
Principal investigator 1 Novo Nordisk AS $9.99 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897114771
Principal investigator 1 Novo Nordisk AS $5.20 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 897115035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,796.00 01/21/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,250.00 01/21/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 01/21/2022 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085845
Principal investigator 1 Novo Nordisk AS $25.06 01/18/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 896961341
Principal investigator 1 ABBVIE INC. $5,097.85 01/06/2022 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889772515